Edit
Melinta Therapeutics
https://melinta.com/melinta-therapeutics-announces-strategic-realignment-and-new-corporate-identity-based-on-strong-scientific-foundation-of-rib-x-pharmaceuticals/Last activity: 20.09.2022
Active
High touch and big impact are trademarks of Melinta. We are nimble and agile without sacrificing our dedication to adding value everywhere we go.
You see, the people of Melinta are believers. Woven into the fiber of our culture is tenacity, brilliance, resilience, excellence and courage. Nothing can weaken our resolve. We take each responsibility seriously, because when we make a move, it matters.
Watch us as we grow. We are the company of the moment and the enterprise of the future. We’re unparalleled in our ability to meet the unmet needs of our patients, and we do so collaboratively. Because we believe the most diverse teams produce the most meaningful impact.
We can’t wait to make legendary strides. Every step counts.
You see, the people of Melinta are believers. Woven into the fiber of our culture is tenacity, brilliance, resilience, excellence and courage. Nothing can weaken our resolve. We take each responsibility seriously, because when we make a move, it matters.
Watch us as we grow. We are the company of the moment and the enterprise of the future. We’re unparalleled in our ability to meet the unmet needs of our patients, and we do so collaboratively. Because we believe the most diverse teams produce the most meaningful impact.
We can’t wait to make legendary strides. Every step counts.
Location: United States, New Jersey, Morristown
Employees: 201-500
Phone: +1 203-624-5606
Total raised: $137M
Founded date: 2000
Investors 3
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Quaker Par... | quakerpart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.06.2015 | - | $67M | - |
| 10.02.2014 | - | $70M | - |
Mentions in press and media 14
| Date | Title | Description |
| 20.09.2022 | Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections | Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's c... |
| 20.09.2021 | Melinta Therapeutics : Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin) | Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was ... |
| 15.03.2021 | Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | MORRISTOWN, N.J.--(BUSINESS WIRE)--Mar 15, 2021-- Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administrat... |
| 04.08.2020 | Could Drug-Resistant Bacteria Cause The Next Pandemic? | Venetians dressed as plague doctors pose during Carnival in their city's Piazza San Marco on ... [+] February 25, 2020. Their costume dates to the Italian Plague of 1629–1631. (Photo by Giacomo Cosua/NurPhoto via Getty Images)NurPhoto via G... |
| 18.03.2020 | Saving lives should be good business. Why doesn’t that apply to finding new antibiotics? | I have spent my career as a biomedical entrepreneur working to develop products that have the potential to save lives while also generating returns for shareholders. Two years ago, I co-founded a new company, Octagon Therapeutics, focused o... |
| 07.01.2020 | Antibiotics need a special place in the drug pricing debate | Melinta Therapeutics, one of the few companies to recently bring a new antibiotic to market, filed for bankruptcy at the end of December. This news comes less than a year after another antibiotic developer, Achaogen, did the same thing. Mor... |
| 20.06.2019 | In starved antibiotic field, Melinta soars as FDA grants speedy drug review | Such is the state of affairs in antibiotic land that the FDA agreeing to priority review an application to expand the use of an antibiotic can rocket up a stock more than two-fold. On Wednesday, Melinta Therapeutics sa... |
| 21.05.2019 | New antibiotics are urgently needed, but economics stand in the way | Achaogen’s journey from promise to penury illustrates the Herculean task the biopharma industry faces: Fulfill a growing need for antibiotics while facing economic realities that make doing so unprofitable. As is apparent from the prolifera... |
| 10.12.2018 | What’s holding pharma back from the next antibiotic breakthrough? | In the five years since the alarm sounded about so-called superbugs, the world has continued to grapple with the staggering health and economic impacts of antibiotic resistance and mounting resistance to antibiotics of last resort. In the U... |
| 10.06.2015 | Melinta Therapeutics Closes $67M in Funding | Melinta Therapeutics, a New Haven, Connecticut-based antibiotics developer, closed $67m in funding. The round was led by Malin Corporation plc with participation from Vatera Healthcare Partners. Proceeds from the financing will be used to c... |
Show more